Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098874338> ?p ?o ?g. }
- W2098874338 abstract "Prolonging kidney transplant survival is an important clinical priority. Induction immunosuppression with antibody therapy is recommended at transplantation and non-depleting interleukin-2 receptor monoclonal antibodies (IL2Ra) are considered first line. It is suggested that recipients at high risk of rejection should receive lymphocyte-depleting antibodies but the relative benefits and harms of the available agents are uncertain.We aimed to: evaluate the relative and absolute effects of different antibody preparations (except IL2Ra) when used as induction therapy in kidney transplant recipients; determine how the benefits and adverse events vary for each antibody preparation; determine how the benefits and harms vary for different formulations of antibody preparation; and determine whether the benefits and harms vary in specific subgroups of recipients (e.g. children and sensitised recipients).Randomised controlled trials (RCTs) comparing monoclonal or polyclonal antibodies with placebo, no treatment, or other antibody therapy in adults and children who had received a kidney transplant.Randomised controlled trials (RCTs) comparing monoclonal or polyclonal antibodies with placebo, no treatment, or other antibody therapy in adults and children who had received a kidney transplant.Two authors independently extracted data and assessed risk of bias. Dichotomous outcomes are reported as relative risk (RR) and continuous outcomes as mean difference (MD) together with their 95% confidence intervals (CI).We included 99 studies (269 records; 8956 participants; 33 with contemporary agents). Methodology was incompletely reported in most studies leading to lower confidence in the treatment estimates.Antithymocyte globulin (ATG) prevented acute graft rejection (17 studies: RR 0.63, 95% CI 0.51 to 0.78). The benefits of ATG on graft rejection were similar when used with (12 studies: RR 0.61, 0.49 to 0.76) or without (5 studies: RR 0.65, 0.43 to 0.98) calcineurin inhibitor (CNI) treatment. ATG (with CNI therapy) had uncertain effects on death (3 to 6 months, 3 studies: RR 0.41, 0.13 to 1.22; 1 to 2 years, 5 studies: RR 0.75, 0.27 to 2.06; 5 years, 2 studies: RR 0.94, 0.11 to 7.81) and graft loss (3 to 6 months, 4 studies: RR 0.60, 0.34 to 1.05; 1 to 2 years, 3 studies: RR 0.65, 0.36 to 1.19). The effect of ATG on death-censored graft loss was uncertain at 1 to 2 years and 5 years. In non-CNI studies, ATG had uncertain effects on death but reduced death-censored graft loss (6 studies: RR 0.55, 0.38 to 0.78). When CNI and older non-CNI studies were combined, a benefit was seen with ATG at 1 to 2 years for both all-cause graft loss (7 studies: RR 0.71, 0.53 to 0.95) and death-censored graft loss (8 studies: RR 0.55, 0.39 to 0.77) but not sustained longer term. ATG increased cytomegalovirus (CMV) infection (6 studies: RR 1.55, 1.24 to 1.95), leucopenia (4 studies: RR 3.86, 2.79 to 5.34) and thrombocytopenia (4 studies: RR 2.41, 1.61 to 3.61) but had uncertain effects on delayed graft function, malignancy, post-transplant lymphoproliferative disorder (PTLD), and new onset diabetes after transplantation (NODAT).Alemtuzumab was compared to ATG in six studies (446 patients) with early steroid withdrawal (ESW) or steroid minimisation. Alemtuzumab plus steroid minimisation reduced acute rejection compared to ATG at one year (4 studies: RR 0.57, 0.35 to 0.93). In the two studies with ESW only in the alemtuzumab arm, the effect of alemtuzumab on acute rejection at 1 year was uncertain compared to ATG (RR 1.27, 0.50 to 3.19). Alemtuzumab had uncertain effects on death (1 year, 2 studies: RR 0.39, 0.06 to 2.42; 2 to 3 years, 3 studies: RR 0.67, 95% CI 0.15 to 2.95), graft loss (1 year, 2 studies: RR 0.39, 0.13 to 1.30; 2 to 3 years, 3 studies: RR 0.98, 95% CI 0.47 to 2.06), and death-censored graft loss (1 year, 2 studies: RR 0.38, 0.08 to 1.81; 2 to 3 years, 3 studies: RR 2.45, 95% CI 0.67 to 8.97) compared to ATG. Creatinine clearance was lower with alemtuzumab plus ESW at 6 months (2 studies: MD -13.35 mL/min, -23.91 to -2.80) and 2 years (2 studies: MD -12.86 mL/min, -23.73 to -2.00) compared to ATG plus triple maintenance. Across all 6 studies, the effect of alemtuzumab versus ATG was uncertain on all-cause infection, CMV infection, BK virus infection, malignancy, and PTLD. The effect of alemtuzumab with steroid minimisation on NODAT was uncertain, compared to ATG with steroid maintenance.Alemtuzumab plus ESW compared with triple maintenance without induction therapy had uncertain effects on death and all-cause graft loss at 1 year, acute rejection at 6 months and 1 year. CMV infection was increased (2 studies: RR 2.28, 1.18 to 4.40). Treatment effects were uncertain for NODAT, thrombocytopenia, and malignancy or PTLD.Rituximab had uncertain effects on death, graft loss, acute rejection and all other adverse outcomes compared to placebo.ATG reduces acute rejection but has uncertain effects on death, graft survival, malignancy and NODAT, and increases CMV infection, thrombocytopenia and leucopenia. Given a 45% acute rejection risk without ATG induction, seven patients would need treatment to prevent one having rejection, while incurring an additional patient experiencing CMV disease for every 12 treated. Excluding non-CNI studies, the risk of rejection was 37% without induction with six patients needing treatment to prevent one having rejection.In the context of steroid minimisation, alemtuzumab prevents acute rejection at 1 year compared to ATG. Eleven patients would require treatment with alemtuzumab to prevent 1 having rejection, assuming a 21% rejection risk with ATG.Triple maintenance without induction therapy compared to alemtuzumab combined with ESW had similar rates of acute rejection but adverse effects including NODAT were poorly documented. Alemtuzumab plus steroid withdrawal would cause one additional patient experiencing CMV disease for every six patients treated compared to no induction and triple maintenance, in the absence of any clinical benefit. Overall, ATG and alemtuzumab decrease acute rejection at a cost of increased CMV disease while patient-centred outcomes (reduced death or lower toxicity) do not appear to be improved." @default.
- W2098874338 created "2016-06-24" @default.
- W2098874338 creator A5004159533 @default.
- W2098874338 creator A5018429053 @default.
- W2098874338 creator A5039834479 @default.
- W2098874338 creator A5042216440 @default.
- W2098874338 creator A5072523142 @default.
- W2098874338 date "2017-01-11" @default.
- W2098874338 modified "2023-10-01" @default.
- W2098874338 title "Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients" @default.
- W2098874338 cites W12864621 @default.
- W2098874338 cites W1487426063 @default.
- W2098874338 cites W1500730394 @default.
- W2098874338 cites W1522262223 @default.
- W2098874338 cites W1543859030 @default.
- W2098874338 cites W1575114019 @default.
- W2098874338 cites W1580373248 @default.
- W2098874338 cites W1618987893 @default.
- W2098874338 cites W1667833568 @default.
- W2098874338 cites W1817052743 @default.
- W2098874338 cites W1864633226 @default.
- W2098874338 cites W1900210699 @default.
- W2098874338 cites W1947608532 @default.
- W2098874338 cites W1955028055 @default.
- W2098874338 cites W1962392014 @default.
- W2098874338 cites W1963731157 @default.
- W2098874338 cites W1964226694 @default.
- W2098874338 cites W1964302059 @default.
- W2098874338 cites W1965556980 @default.
- W2098874338 cites W1966299088 @default.
- W2098874338 cites W1967915560 @default.
- W2098874338 cites W1970702399 @default.
- W2098874338 cites W1977704993 @default.
- W2098874338 cites W1979317720 @default.
- W2098874338 cites W1983211062 @default.
- W2098874338 cites W1983551177 @default.
- W2098874338 cites W1984977652 @default.
- W2098874338 cites W1988816408 @default.
- W2098874338 cites W1995791071 @default.
- W2098874338 cites W1996223700 @default.
- W2098874338 cites W1997862417 @default.
- W2098874338 cites W2000138932 @default.
- W2098874338 cites W2000788047 @default.
- W2098874338 cites W2001782250 @default.
- W2098874338 cites W2002017516 @default.
- W2098874338 cites W2002358655 @default.
- W2098874338 cites W2002512576 @default.
- W2098874338 cites W2003952289 @default.
- W2098874338 cites W2004328035 @default.
- W2098874338 cites W2006132026 @default.
- W2098874338 cites W2006155832 @default.
- W2098874338 cites W2006499806 @default.
- W2098874338 cites W2006861834 @default.
- W2098874338 cites W2008489253 @default.
- W2098874338 cites W2009596182 @default.
- W2098874338 cites W2010390181 @default.
- W2098874338 cites W2012014582 @default.
- W2098874338 cites W2012994294 @default.
- W2098874338 cites W2013875966 @default.
- W2098874338 cites W2014452295 @default.
- W2098874338 cites W2014605498 @default.
- W2098874338 cites W2015858533 @default.
- W2098874338 cites W2016453244 @default.
- W2098874338 cites W2016520408 @default.
- W2098874338 cites W2017545412 @default.
- W2098874338 cites W2018100390 @default.
- W2098874338 cites W2020165265 @default.
- W2098874338 cites W2021486503 @default.
- W2098874338 cites W2022089959 @default.
- W2098874338 cites W2022293788 @default.
- W2098874338 cites W2023081372 @default.
- W2098874338 cites W2027511687 @default.
- W2098874338 cites W2028348045 @default.
- W2098874338 cites W2028965877 @default.
- W2098874338 cites W2031727025 @default.
- W2098874338 cites W2032611005 @default.
- W2098874338 cites W2034181212 @default.
- W2098874338 cites W2035938515 @default.
- W2098874338 cites W2036263745 @default.
- W2098874338 cites W2036573087 @default.
- W2098874338 cites W2036819635 @default.
- W2098874338 cites W2038449618 @default.
- W2098874338 cites W2038838900 @default.
- W2098874338 cites W2043152356 @default.
- W2098874338 cites W2045752685 @default.
- W2098874338 cites W2045902680 @default.
- W2098874338 cites W2046164377 @default.
- W2098874338 cites W2048034264 @default.
- W2098874338 cites W2051844016 @default.
- W2098874338 cites W2051932458 @default.
- W2098874338 cites W2052307789 @default.
- W2098874338 cites W2053196006 @default.
- W2098874338 cites W2055577060 @default.
- W2098874338 cites W2055613782 @default.
- W2098874338 cites W2056577857 @default.
- W2098874338 cites W2056842975 @default.
- W2098874338 cites W2058150151 @default.
- W2098874338 cites W2063759059 @default.
- W2098874338 cites W2063817866 @default.
- W2098874338 cites W2065991128 @default.